Nausheen Ahmed, MD

Although data for bispecific antibodies are maturing, CAR T-cell therapy has longer-term data that show prolonged and durable efficacy in LBCL.

Whereas CAR T-cell therapies need weeks to be engineered, bispecific therapies can be ready much quicker for patients with progressing non-Hodgkin lymphoma.

CRS and ICANS may affect patients with lymphoma regardless of whether they receive CAR T or bispecific antibodies, although severity and timing will vary.

Experts at the 2025 National ICE-T Conference discussed the need for improved management of toxicities in patients with leukemia.

A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.

A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.

A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.

Nausheen Ahmed, MD, discusses findings from a study supporting reduced monitoring windows for patients with lymphoma who receive CAR T-cell therapy.

The expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.

Nausheen Ahmed, MD, gives an overview of BCMA bispecific T-cell engagers used in the treatment of multiple myeloma.

Experts on multiple myeloma discuss the mechanism of action and adverse events for teclistamab and compare CAR T-cell therapy with bispecific T-cell engagers (BiTEs).

The expert panel discusses CAR T-cell therapy options and treatment considerations for patients with multiple myeloma.

Al-Ola Abdallah, MD, presents the case of a patient with multiple myeloma treated with CAR T-cell therapy and teclistamab.

Nausheen Ahmed, MD, and Al-Ola Abdallah, MD, discuss the use of CAR T-cell therapy in patients with transplant-ineligible multiple myeloma.

The expert panel gives an overview of factors that influence treatment decisions in patients with transplant-ineligible multiple myeloma.

Leyla O. Shune, MD, reviews the MAIA trial, which looked at DRd vs Rd in patients with transplant-ineligible multiple myeloma.

The expert panel presents the case of a patient with multiple myeloma and discusses evaluating transplant eligibility in patients with MM.

The standard of care for high-risk multiple myeloma remains unsettled, according to an expert panel from Kansas City.

Experts on multiple myeloma offer clinical insights on treatment options and considerations for patients with standard- and high-risk multiple myeloma.

Nausheen Ahmed, MD, discusses the measurement of treatment response following induction therapy in patients with multiple myeloma.

The expert panel provides clinical insights on the key features of high-risk multiple myeloma and a look toward the clinical trial landscape.

Clinical experts examine the role of transplant in multiple myeloma and discuss key clinical trials and the impact of adding daratumumab to triplet therapy.

Experts on multiple myeloma discuss recent updates from the GRIFFIN trial on patients with transplant-eligible multiple myeloma.

A panel of clinical experts presents the case of a patient with high-risk multiple myeloma (MM) who underwent transplant.